ArticleBiosensors2025
Exploration of the Tolerance of Novel Coronaviruses to Temperature Changes Based on SERS Technology.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Motivated by the rapid development of SERS technology, trace detection of various viruses in the sewage and body fluid environments and accurate positive and negative diagnosis of detection samples can be achieved. However, evaluating the environmental survival ability of viruses based on SERS technology remains an unexplored issue, but holds significant guiding significance for effective epidemic prevention and control as well as inactivation treatment. In this work, Au nanoarrays were fabricated on silicon substrates through a simple Ar ion sputtering route as ultra-sensitive SERS chips. With the synergistic contribution of the "lightning rod" effect and the enhanced coupling surface plasmon caused by the nanoarrays, the ultra-sensitive detection of SARS-CoV-2 S protein with a concentration of 1 pg/mL and SERS enhancement factor of 4.89 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.